Status:
UNKNOWN
AIDA2000 - Risk-Adapted Therapy for Patients With Acute Promyelocytic Leukemia
Lead Sponsor:
Technische Universität Dresden
Conditions:
Leukemia, Promyelocytic, Acute
Eligibility:
All Genders
16+ years
Phase:
PHASE4
Brief Summary
In AIDA 2000 therapy of acute promyelocytic leukemia (APL) is given in a risk-adapted manner. Risk factors are age and white-blood-cell (WBC)-count at diagnosis. Induction therapy is done with ATRA an...
Detailed Description
In AIDA 2000 therapy of acute promyelocytic leukemia (APL) is given in a risk-adapted manner. Risk factors are age and white-blood-cell (WBC)-count at diagnosis. Induction therapy is done with ATRA an...
Eligibility Criteria
Inclusion
- acute promyelocytic leukemia confirmed by detection of t(15;17) and/or PML/RARa
- no contraindication for chemotherapy
- written informed consent
Exclusion
- \- severe comorbidities
Key Trial Info
Start Date :
January 1 2000
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2012
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT00180128
Start Date
January 1 2000
End Date
November 1 2012
Last Update
July 11 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Medicine I, University Hospital Carl Gustav Carus
Dresden, Germany, 01307